Role of Stem Cells in Pathophysiology and Therapy of Spondyloarthropathies-New Therapeutic Possibilities?

• Published in: International journal of molecular sciences Vol. 19; no. 1; p. 80
• Main Authors: Krajewska-Włodarczyk, Magdalena, Owczarczyk-Saczonek, Agnieszka, Placek, Waldemar, Osowski, Adam, Engelgardt, Piotr, Wojtkiewicz, Joanna
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 28.12.2017; MDPI
• Subjects: Ankylosing spondylitis; Arthritis; Bone growth; Inflammation; Interleukin 12; Interleukin 17; mesenchymal stem cells; Mesenchyme; Osteogenesis; Pathogenesis; Psoriatic arthritis; Review; Spondylitis; spondyloarthropathies; Spondyloarthropathy; Stem cells; Stromal cells; Tumor necrosis factor; Tumor necrosis factor-α; inflammation; mesenchymal stem cells; spondyloarthropathies
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms19010080

Considerable progress has been made recently in understanding the complex pathogenesis and treatment of spondyloarthropathies (SpA). Currently, along with traditional disease modifying anti-rheumatic drugs (DMARDs), TNF-α, IL-12/23 and IL-17 are available for treatment of such diseases as ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Although they adequately control inflammatory symptoms, they do not affect the abnormal bone formation processes associated with SpA. However, the traditional therapeutic approach does not cover the regenerative treatment of damaged tissues. In this regards, stem cells may offer a promising, safe and effective therapeutic option. The aim of this paper is to present the role of mesenchymal stromal cells (MSC) in pathogenesis of SpA and to highlight the opportunities for using stem cells in regenerative processes and in the treatment of inflammatory changes in articular structures.